Patients Are Complex—
Choosing a Stent Shouldn't Be

“The next generation of XIENCE [Sierra] will greatly improve acute performance.”

 Aloke Finn, MD 

XIENCE Sierra Best-in-Class Deliverability

With XIENCE Sierra's new stent design, the XIENCE reputation now extends to offer unmatched deliverability, even with challenging complex lesions.

73% less force
to cross a lesion than SYNERGY 64% less force than Resolute Onyx 

Optimized Multi-link 
stent design allows for tighter crimping and smoother crossing

Thinner balloon 
provides maximum flexibility and further lowers crimped profile

Ultra low stent crossing profile1 of 0.039″ for Easier Crossing 
enabled by the new stent design and balloon technology1

Ultra low stent crossing profile1 of 0.039″
for Easier Crossing
 

enabled by the new stent design and balloon technology1

XIENCE Sierra's exceptional deliverability also comes from the enhanced stent delivery system featuring a single-piece outer member for added pushability and trackability.

Experts' Point of View

XIENCE Sierra: Difference in Deliverability

“[In a tortuous lesion] the difference was amazing with XIENCE Sierra — like smooth sailing down a rough patch.”

Roxana Mehran, MD

Play video

 

Expanded Treatment Options

With 5.5 mm post-dilatation capability for 3.5 mm and 4.0 mm stents, XIENCE Sierra can treat most large vessels.

 

UNIQUELY DESIGNED
to post-dilate up to 5.5 mm

UNIQUELY DESIGNED
to post-dilate up to 5.5 mm

With 3.75 mm post-dilatation capability for 2.0 mm, 2.25 mm, 2.5 mm, 2.75 mm, 3.0 mm, and 3.25 mm stents, XIENCE Sierra can also treat tapered vessels of various diameters.

Shortening

Provides unsurpassed precision in placement and avoid geographic miss 
zero shortening even at max expansion of 5.5 mm2

XIENCE Sierra ensures coating integrity3
even at max expansion

XIENCE Sierra

coating remains intact at maximum post-dilatation expansion
of 5.5 mm from 3.5 mm 

XIENCE Sierra (3.5 x 18 mm) 
25x magnification at max expansion
of 5.5 mm 

XIENCE Sierra (3.5 x 18 mm)
150x magnification at max expansion
of 5.5 mm 

Synergy

coating shows multiple cracks with delamination at its max
expansion of 4.25 mm from 3.5 mm  

SYNERGY (3.5 x 20 mm) 
25x magnification at max expansion
of 4.25 mm 

SYNERGY (3.5 x 20 mm) 
150x magnification at max expansion
of 4.25 mm 

Resolute Onyx

coating peels off and shows exposed metal at its max
expansion of 4.75 mm from 3.5 mm  

Resolute ONYX (3.5 x 18 mm) 
25x magnification at max expansion
of 4.75 mm 

Resolute ONYX (3.5 x 18 mm) strut,
150x magnification, after
post-dilated to 4.75 mm

Experts' Point of View

XIENCE Sierra Post-Dilatation Capability

"[This device] with better deliverability and a better range of choices . . . is clearly good news."

Florim Cuculi, MD

Play video


Unparalleled Safety4 for Even the Most Challenging Lesions

XIENCE showed significant benefit compared to several DES and composite BMS in multiple large scale meta-analysis and other RCTs.

Evidence of XIENCE's safety is reflected in consistently low stent thrombosis rates of 0.5%-0.7% for many subgroups of complex patients, such as those with chronic total occlusions5-10.

In fact, throughout the years, physicians appreciated the proven safety of XIENCE stents: 

“The everolimus-eluting stent was the safest stent.” (Circulation, 2012

— Sripal Bangalore, MD11

Experts' Point of View

XIENCE Fluoropolymer Coating Adheres Without Peeling

"XIENCE is the safest stent so far — repeatedly the rate of thrombosis is very, very low."

Manel Sabaté, MD

(Testimonial recorded on May 18th, 2017 at PCR)

Play video


Learn more about XIENCE Sierra

You can contact your sales representative to learn more about XIENCE Sierra. You can also order XIENCE Sierra to suit a broad spectrum of patient needs.  

Get the latest data

Sign up to receive the latest about XIENCE study results as they become available.


SIGN UP
Sign up

 Bench test data shows that XIENCE Sierra performed better in crossability and was not statistically different in trackability and pushability compared to Resolute Onyx and SYNERGY stents. Bench test results may not necessarily be indicative of clinical performance. Test performed by and data on file at Abbott. Testing performed on XIENCE Sierra Everolimus Eluting Coronary Stent System (3.0 x 18 mm) n=5, SYNERGY Stent System (3.0 x 20 mm) n=5, Resolute Onyx Stent System (3.0 x 18 mm) n=5. Catheter performance crossability test measures average force to cross a challenging lesion model.

‡ Increased maximum expansion compared to other XIENCE Everolimus Eluting Coronary Stent System.

  1. 
Test performed by and data on file at Abbott. XIENCE Sierra Everolimus Eluting Coronary Stent System (3.0 x 18 mm) n=5, SYNERGY Stent System (3.0 x 20 mm) n=5, Resolute Onyx Stent System (3.0 x 18 mm) n=5.
  2. Test performed by and data on file at Abbott. XIENCE Sierra Everolimus Eluting Coronary Stent System (4.0 x 18 mm) n=5, SYNERGY Stent System (4.0 x 20 mm) n=5, Resolute Onyx Stent System (4.5 x 18 mm) n=5.
  3. Test performed by and images on file at Abbott.
  4. Palmerini, et al. The Lancet. 379:9824, 14-20 April 2012, pp. 1393-1402; Bangalore S, et al. Circ Cardiovasc Interv, Aug 6, 2013. doi: 10.1161/ circinterventions.113.000415.; Valgimigli, Effects of Cobalt-chromium Everolimus eluting or bare metal stent on fatal and non-fatal cardiovascular events. A patient-level meta analysis. EuroPCR 2014; Serruys, PW et al. RESOLUTE All Comers Trial, NEJM 2010. Published online June 16, 2010; Fajadet, J., et al. PLATINUM PLUS 30-day Poster, TCT 2012.
  5. Stone, G. “EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients with Left Main Coronary Artery Disease.” Presented Oct. 31, 2016 at TCT.
  6. Teeuwen, K. “Hybrid Sirolimus-eluting Stents with Biodegradable Polymer versus Everolimus eluting Stents with Durable Polymer in Chronic Total Occlusions (PRISON IV).” Presented Nov
  7. Lam, M. Three-year clinical outcome of patients with bifurcation treatment with second-generation Resolute and XIENCE V stents in the randomized TWENTE trial. American Heart Journal. Vol 169: No 1, Jan 2015.
  8. 2016 at TCT. 2. U Kaul. “Last Word on DES in Diabetics: Two Year TUXEDO Outcomes.” Presented on Oct. 30, 2016 at TCT.
  9. M. Sabaté. Everolimus-eluting stents versus bare metal stents in ST-segment elevation myocardial infarction. Five-year results of the EXAMINATION Trial. ESC 2015.
  10. de Belder A, et al. XIMA Trial. JACC. 2014;63:1371-1375.
  11. Bangalore S, et al. Circulation. June 2012. DOI: 10.1161/CIRCULATIONAHA.112.097014.

You are about to leave the Abbott family of websites for a third party website.

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit the website?

Disclaimer

Xiencestent.com is a product-specific website that is NOT intended for U.S. residents. This web content is exclusively reserved for health care professionals in countries with applicable health authority product registrations.

If you are a resident of a country other than those to which the site is directed, please contact your local Abbott affiliate to obtain the appropriate product information for your country of residence.

Do you wish to continue to visit the International section of this website?